Company: DNLI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001714899-25-000066
Chunk: 184

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 184
---
 per share, basic and diluted$(2.57)$(1.06)$(2.60)Weighted average number of shares outstanding, basic and diluted164,473,772 137,370,897 125,530,703 

__________________________________________________

(1)Includes related-party collaboration revenue from customers of $295.5 million, and $3.2 million for the years ended December 31, 2023 and 2022, respectively.

(2)Includes expense for cost sharing payments to a related party of $17.7 million and $8.2 million for the years ended December 31, 2023 and 2022, respectively.

See accompanying notes to consolidated financial statements.

138

Denali Therapeutics Inc.

Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive Income (Loss)Accumulated DeficitTotal Stockholders' Equity SharesAmountBalance at December 31, 2021122,283,305 $1,548 $1,608,238 $(2,499)$(644,996)$962,291 Issuance of common stock in follow-on offering, net of issuance costs of $1,06011,933,962 120 296,095 — — 296,215 Issuances under equity incentive plans911,555 10 14,445 — — 14,455 Vesting of restricted stock units837,096 8 (8)— — — Stock-based compensation— — 99,847 — — 99,847 Net loss— — — — (325,991)(325,991)Other comprehensive loss— — — (4,387)— (4,387)Balance at December 31, 2022135,965,918 $1,686 $2,018,617 $(6,886)$(970,987)$1,042,430 Issuances under equity incentive plans1,232,526 12 17,808 — — 17,820 Vesting of restricted stock units1,187,054 13 (13)— — — Stock-based compensation— — 108,399 — — 108,399 Net loss— — — — (145,224)(